Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

3SBio and Verseau Choose First Candidate in Microphage Immunotherapy Partnership

publication date: Nov 19, 2019

3SBio of Shenyang selected the first immunoncology candidate to develop in greater China from its partnership with Boston's Verseau Therapeutics, a company developing macrophage checkpoint modulators (MCMs). VTX-0811 targets PSGL-1, an adhesion molecule highly expressed on tumor-associated macrophages in most tumor types. Verseau says PSGL-1 antibodies cause a bigger inflammatory response than current immunotherapies. 3SBio acquired rights to several Verseau candidates by investing $15 million in Verseau's $50 million funding last month. More details....

Stock Symbol: (HK: 1530)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.